- Home
- CIVI vs HCM Comparison
CIVI vs HCM Comparison
Compare CIVI & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIVI | HCM |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | CIVI | HCM |
|---|---|---|
| Price | $25.79 | $14.70 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 13 | 1 |
| Target Price | ★ $40.80 | $13.75 |
| AVG Volume (30 Days) | ★ 1.4M | 40.5K |
| Earning Date | 02-23-2026 | 08-07-2025 |
| Dividend Yield | ★ 7.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.86 | 0.53 |
| Revenue | ★ $4,711,808,000.00 | $602,197,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.54 |
| P/E Ratio | ★ $3.84 | $5.39 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.79 | $11.51 |
| 52 Week High | $55.35 | $19.50 |
Technical Indicators
Market Signals| Indicator | CIVI | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 38.64 | 63.17 |
| Support Level | $25.38 | $13.20 |
| Resistance Level | $26.75 | $15.00 |
| Average True Range (ATR) | 0.95 | 0.40 |
| MACD | -0.14 | 0.21 |
| Stochastic Oscillator | 11.39 | 85.56 |
Price Performance
Historical ComparisonAbout CIVI Civitas Resources Inc.
Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado - DJ Basin. The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.